22 results about "Blood level" patented technology

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

Described herein are methods and devices for monitoring or modulating an immune system in a subject with cancer, and methods and devices for treating a cancer in a subject. The implanted device can electrically stimulate the splenic nerve of the subject, which can modulate the inflammatory system (for example, by increasing or decreasing the blood level of one or more pro-inflammatory cytokines and / or anti-inflammatory cytokines to increase or decrease inflammation in the subject) and / or activate or increase circulation of one or more immune cells (such as natural killer cells and / or cytotoxic T-cells), for the treatment of cancer. The implanted medical device includes two or more electrodes configured to electrically stimulate the splenic nerve, and may further include an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device.

An electronic device comprises a housing configured to contact a user's skin, an optical transmitter array, an optical receiver, a memory element and a processing element. The optical transmitter array outputs a plurality of optical signals that pass through the user's skin, each of the plurality of optical signals having one of three wavelengths. The optical receiver receives the optical signals and generates corresponding photoplethysmogram (PPG) signals. The memory element stores absorption constants for deoxyhemoglobin blood content, oxyhemoglobin blood content and glycated hemoglobin blood content, each absorption constant associated with one of the first wavelength, the second wavelength or the third wavelength. The processing element determines a glycated hemoglobin blood level for the user based on a ratio of a determined glycated hemoglobin blood content to a sum of determined deoxyhemoglobin blood content, a determined oxyhemoglobin blood content and a determined glycated hemoglobin blood content.

Methods of treating idiopathic nephrotic syndrome in a subject involve reducing urinary and / or blood levels of CD93, reducing or inhibiting CD93-mediated podocyte activation. or reducing or inhibiting CD93 release from glomerular endothelial cells. The methods may include administration of a composition including at least one of an anti-CD93 antibody and an inhibitor of pi integrin.

Methods of using inhibitors of receptor for advanced glycation end products (RAGE) to treat a subject who has an inflammatory disorder are provided. The methods include use of the small molecule RAGE inhibitor azeliragon to reduce blood levels of cytokines including TNF-p, IL-6, IL-2, IL- 12 p70, IL-12 p40, IL-13 and IFNy, thereby ameliorating the clinical manifestations of an inflammatory disorder.

Methods of using inhibitors of receptor for advanced glycation end products (RAGE) to treat a subject who has an inflammatory disorder are provided. The methods include use of the small molecule RAGE inhibitor azeliragon to reduce blood levels of cytokines including TNF-β, IL-6, IL-2, IL- 12 p70, IL-12 p40, IL-13 and IFNγ, thereby ameliorating the clinical manifestations of an inflammatory disorder.

Provided in the present application are an autologous blood reinfusion system and method. The system comprises a collection module, a storage module, an output module, and a control module, wherein the collection module is configured to collect blood from a target subject and transfer the blood to the storage module; the storage module is configured to store the blood and acquire a blood level height value; the output module comprises a first driving unit, a filtering unit, and a first pressure monitoring unit, the first driving unit being configured to deliver the blood in the storage module to the filtering unit, the filtering unit being configured to filter the blood and deliver the filtered blood to the target subject, and the first pressure monitoring unit being configured to acquire a first pressure value of the filtering unit; and the control module is configured to compare the blood level height value with a first threshold, and send a stop signal to the first driving unit when the blood level height value is less than the first threshold, and is further configured to compare the first pressure value with a second threshold, and send a stop signal to the first driving unit when the first pressure value is greater than the second threshold.

The present invention relates to agglomerates of soluble whey protein aggregates for use in the treatment and / or prevention of one or more conditions linked to GLP-1 blood levels in a human subject.

To provide a suitable means for delivering a therapeutic biomolecule to a patient, wherein a stable and therapeutically effective blood level of the biomolecule occurs in a stable and convenient form over an extended period of time.SOLUTION: Provided is a device for treating a disease in a subject, wherein the subject may have Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, eosinophilic esophagitis, autoimmune hepatitis, the device comprising a cell chamber comprising a population of cells that secrete a biomolecule for delivery to the subject.SELECTED DRAWING: None

Provided is a computer-implemented method for selecting a subject at risk for developing Crohn's disease, including a trained logistic regression model classifying a subject as at risk for developing Crohn's disease based on blood levels of C-X-C motif chemokine ligand (9), transforming growth factor α, hepatocyte growth factor, C-C motif chemokine ligand (11), matrix metalloproteinase (10), matrix metalloproteinase (1), C-X-C motif chemokine ligand (11), C-C motif chemokine ligand (19), C-C motif chemokine ligand (23), and tumor necrosis factor β.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating acute ischemic stroke and a preparation method thereof. The traditional Chinese medicine composition is prepared from rheum officinale, ground beetles, fructus trichosanthis, angelica sinensis, immature bitter oranges, arisaema cum bile and leeches, in the formula, the rheum officinale serves as a monarch drug and has the effects of relaxing bowels, purging heat and washing away phlegm, so that the effects of smoothing middle energizer and regulating qi activity are achieved; the immature bitter orange is used as a ministerial drug, assists the rhubarb in descending qi and relaxing bowels, and also can relieve qi and remove food retention, and eliminate dampness and phlegm; the fructus trichosanthis and the arisaema cum bile have the effects of clearing heat and eliminating phlegm, the arisaema cum bile has the effects of removing stasis and dredging collaterals, and the ground beetles and the leeches are matched to break blood and remove stasis and clear and activate the channels and collaterals and serve as adjuvant drugs; the whole angelica sinensis nourishes and activates blood, disperses blood stasis and dredges vessels, introduces all the medicines into blood and serves as a guide medicine. The whole prescription is small in dosage, specific in force, light in weight, heavy in taste, capable of regulating blood and qi simultaneously, capable of treating both symptoms and root causes, capable of regulating qi and dredging collaterals, removing blood stasis and stagnation, capable of clearing phlegm heat and remarkable in treatment effect on acute ischemic stroke.

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sEng antibody bound to a solid support in order to reduce blood levels of sEng. The present invention provides a method of treating or preventing a disorder associated with soluble Endoglin (sEng), such as a pregnancy-related hypertensive disorder, in a subject in need thereof comprising providing ex vivo to the subject anti-sEng antibodies or sEng-binding fragments thereof in an amount sufficient and for a time sufficient to decrease the subject's blood levels of sEng to treat or prevent the disorder associated with sEng in the subject.

A method of mimicking health benefits of physical exercise or voluntary cold exposure, e.g., cold plunge, in an animal can include administering to the animal a high protein diet including from about 150% to about 400% of a Recommended Daily Allowance (RDA) of protein for the animal on a daily basis. The high protein diet can be sufficient to increase a 12,13-diHOME blood level for an 18-24 hour period per day compared to a baseline blood level without the need for the physical exercise or voluntary cold exposure.

This application relates to a vascular artificial embolism formation and control system. The system includes an embolism pressure control component, a gas pipeline, a liquid level adjustment component, and a liquid pipeline. The embolism pressure control component controls the gas pressure and volume of the artificial embolism; the liquid level adjustment component includes a liquid extraction control element and a liquid collection container, used to adjust the blood level in the blood vessel after the artificial embolism at the required pressure is formed, thereby controlling the position of the artificial embolism within the blood vessel. This control system can precisely control the gas pressure, gas volume, and position of the artificial embolism in the blood vessel, overcoming the problem of blood backflow during the retrograde movement of the artificial embolism, and significantly reducing the risk of the artificial embolism entering the circulatory system through collateral circulation, effectively preventing the possibility of gas embolism causing harm to other parts of the body; it also reduces the consumption of artificial embolism gas and the loss of blood from the patient during the procedure.

The present invention relates to a parenteral composition of Linagliptin or its salt and one or more pharmaceutically acceptable excipient. The parenteral composition of Linagliptin or its salt and one or more pharmaceutically acceptable excipient provide immediate response, minimization of side effect, improving bioavailability and achieving the desired drug blood level rapidly and provide better patient compliance in the treatment of type 2 diabetes mellitus.

Described are methods related to the use of vitamin E as a clinical marker in subjects suffering from severe hypertriglyceridemia. One particular method comprises measuring a level of vitamin E in a subject's blood suffering from severe hypertriglyceridemia to assess a blood level of chylomicrons-related triglycerides. Another particular method comprises measuring a level of vitamin E in a subject's blood suffering from severe hypertriglyceridemia to distinguish between triglycerides and lipoproteins issued from the exogenous pathway versus those of the endogenous pathway. Another particular method comprises measuring vitamin E in a subject suffering from severe hypertriglyceridemia for assessing whether hypolipidemic treatments are effective or not, and to which extent. Another particular method is for assessing a risk of acute pancreatitis in a subject suffering from hypertriglyceridemia. Also described is a method for assessing vitamin E deficiency and kits comprising vitamin E.

The invention relates to the technical field of biomedical parameter regulation and control, in particular to an electrical stimulation and ultrasound synergistic acupoint dynamic regulation and control system. The data acquisition module is used for collecting physical sign parameters, qi and blood level time sequence data and operation parameters (electrical stimulation and ultrasonic intensity) and acupuncture point combinations before and after each acupuncture; the physical sign contribution degree analysis module compares the fluctuation of the physical sign parameters before and after acupuncture, and quantifies the contribution degree of each physical sign parameter to the curative effect in combination with Qi and blood level change correlation analysis; the operation intensity analysis module analyzes the association between the effect feedback of the operation parameters and the sign parameters in the historical acupuncture process under the same acupuncture point combination, determines the parameter intensity weight, and determines the response degrees of electrical stimulation and ultrasound under different acupuncture point combinations; and the dynamic regulation and control module fuses the current physical sign data, the qi and blood state, the contribution degree and the intensity weight, and automatically adjusts the preset intensity of electrical stimulation and ultrasound to adapt to the state difference of the patient and the dynamic change of physical signs and qi and blood in the treatment process.

The present invention includes a method for determining whether a subject diagnosed with osteoarthritis is at increased risk for progression to severe osteoarthritis within 12-24 months, the method comprising the steps of: (a) preparing a blood sample; (b) measuring in the blood sample prepared in step (a) a level of DNA methylation; (c) comparing the DNA methylation level(s) measured in step (b) to a control blood sample level(s) of DNA methylation, and (d) identifying the subject as being at increased risk for progression to severe osteoarthritis within 12-24 months when the DNA methylation is increased by at least 2 fold as compared to the control blood level(s) of DNA methylation.

A method of mimicking health benefits of physical exercise in a cat can include administering a high protein diet to a cat, the high protein diet including from about 110% to about 350% of a Recommended Daily Allowance (RD A) of protein for the cat on a daily basis. The high protein diet in this example is sufficient to increase a 12,13-diHOME blood level for an 18-24 hour period per day compared to a baseline blood level without the need for physical exercise.

A method of mimicking health benefits of physical exercise or voluntary cold exposure, e.g., cold plunge, in an animal can include administering to the animal a high protein diet including from about 150% to about 400% of a Recommended Daily Allowance (RD A) of protein for the animal on a daily basis. The high protein diet can be sufficient to increase a 12,13-diHOME blood level for an 18-24 hour period per day compared to a baseline blood level without the need for the physical exercise or voluntary cold exposure.

The present disclosure provides a combination of a liposomal suspension, and of albumin, for use as bile acid sequestrants, wherein the use comprises (a) intraperitoneally administering the liposomal suspension to a subject in need thereof; and (b) intravenously or intraperitoneally administering the albumin to the subject; and (c) removing a dialysate containing liposomes and at least one bile acid from the subject, wherein the at least one bile acid comprises cholic acid, glycocholic acid, glycochenodeoxycholic acid or a combination of at least two thereof.

A paper-based analytical device for potentiometric assay of Arylsulfatase A (ARSA) activity levels. The analytical device comprises a filter paper substrate supporting a potentiometric cell, a reference electrode, and an ion-selective electrode. The electrodes are constructed using an ink comprising carbon nanotubes and reduced graphene oxide (r-GO). The analytical device also includes a solid-contact potentiometric sensor for ARSA integrated with the electrodes and a polymeric membrane associated with the ion-selective electrode. The analytical device is capable of providing results from actual serum and whole blood samples. A method for monitoring blood ARSA levels and a method for fabricating the analytical device are also disclosed.